Inhaled vasodilator

This page covers all Inhaled vasodilator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Soluble guanylate cyclase (via nitric oxide signaling), Soluble guanylate cyclase, Soluble guanylate cyclase / cGMP pathway.

Targets

Soluble guanylate cyclase (via nitric oxide signaling) · Soluble guanylate cyclase · Soluble guanylate cyclase / cGMP pathway

Marketed (3)

• Crossover iNO · University of Florida · Pulmonary/Respiratory
  Crossover iNO is an inhaled nitric oxide delivery system that increases nitric oxide levels in the lungs to improve oxygenation and reduce pulmonary vascular resistance.
• Inhaled Nitric Oxide (iNO) use · The University of Texas Health Science Center, Houston · Pulmonary/Cardiovascular
  Inhaled nitric oxide is a vasodilator gas that selectively relaxes pulmonary vascular smooth muscle to reduce pulmonary hypertension and improve oxygenation.
• iNO · Wake Forest University Health Sciences · Critical Care / Respiratory
  iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure.

Phase 3 pipeline (1)

• Nitric Oxide plus Oxygen · Mallinckrodt · Cardiovascular / Pulmonary
  Nitric oxide gas combined with oxygen improves oxygenation and vasodilation in the lungs to reduce pulmonary hypertension and improve gas exchange.